NCT04463589Completed
Presenteeism in Severe Asthma Treated by Biotherapyasthma
Factors Associated With the Evolution of Presenteeism Under Biotherapy in Severe Asthma
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
Severe asthma is a condition characterized by a lower sensitivity to high doses of inhaled corticosteroids combined with a second controller, most often a long-acting bronchodilator. It concerns approximately 5% of asthmatics. Treatment failure and co-morbidities induced by systemic corticosteroid therapy can cause debilitating dyspnea, limited physical activity, and impaired quality of life. Severe asthma could therefore be associated with major presenteeism, defined as the presence of an employee at work despite his health issues and which implies a limitation of the employee's productive capacity. Uncontrolled asthma and co-morbidities of asthma have been shown to be associated with a decrease in work productivity that includes absenteeism and presenteeism. Although there is little data, a recent study found a decline in work productivity in severe asthma. Various factors associated with presenteeism could be involved, such as asthma control, frequency and severity of exacerbations, comorbidities, or treatments. Biotherapies targeting the signaling pathways involved in airway inflammation improve asthma control, decrease the frequency of asthma exacerbations which are major determinants of quality of life, improve lung function, and allow oral steroid sparing. Biotherapies could therefore be associated with a decrease in presenteeism. The objective of the study is to describe the evolution of presenteeism at work, evaluated by the WPAI: Asthma, after 6 months of treatment by biotherapy and to identify factors associated with this evolution
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 174 (actual)
- First submitted
- 2 Jul 2020
- Start date
- 1 Jan 2021
- Primary completion date
- 10 Jun 2024
- Lead sponsor
- University Hospital, Lille
- Diseases
- Asthma
- NCT number
- NCT04463589
What you commit to
- Study type: Observational
- Participants enrolled: 174
- From 1 Jan 2021 to the primary completion date, 10 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Existence of another chronic pulmonary disease (bronchiectasis, COPD, diffuse interstitial lung disease, neuromuscular pathology, etc.) or cardiac (cardiac rhythm disorder, ischemic heart disease, etc.) significant according to the investigator's judgment
- Psychiatric disorder
Other
- Pregnancy
- Persons under guardianship
Who the study is looking for
- Severe asthma defined as the use of a high doses of inhaled corticosteroids combined with a second controller (GINA 4) and / or oral corticosteroid therapy \> 50% of the year
- Eligible for biotherapy according to the investigator's decision
- Holders of an employment contract for at least 8 days
- Written non-opposition to participate in the study after information
- Social protection affiliation
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hop Calmette Chu Lille Coordinator of this site? Confirm its status | Lille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.